Sucharita Mistry, PhD

A high neutrophil-lymphocyte ratio appears to be an independent predictor of outcomes for some patients with head and neck cancer.

The risk score can improve upon EBV-based screening, according to researchers.

Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.

Three biomarkers were associated with prognosis after COVID-19 treatment.

Patients with lymph node ratios of 9% or higher had better overall survival when they received adjuvant chemotherapy.

Pembrolizumab plus chemotherapy did not improve overall survival in patients with a PD-L1 combined positive score below 1.

Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.

Camrelizumab improved overall survival, even when adjusting for crossover.

Despite the lack of improvement in the overall cohort, olaparib monotherapy and olaparib-cediranib did exhibit activity in a subset of patients with a germline BRCA mutation.

Researchers evaluated the impact of African ancestry on the relationship between body mass index and survival in early breast cancer.